Evidence map›Paper›PMID 17615182›Full record

ArticleBMJ (Clinical research ed.)2007

Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study.

Julia Hippisley-Cox, Carol Coupland, Yana Vinogradova, John Robson, Margaret May, Peter Brindle

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyValidation Study
In one paragraph

Article in BMJ (Clinical research ed.), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04189497 (Development of a Prognostic Tool for the Stratification of Cardiovascular Risk in Patients With Ischemic Stroke), which is not on this map. Cited by 419 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
419citing papers in PubMed, 4 pooled it
46.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04189497 completednot on this mapstarted 2019, after this paper: background citation

Development of a Prognostic Tool for the Stratification of Cardiovascular Risk in Patients With Ischemic Stroke

TypeobservationalSponsorUniversity of ThessalyRan2019 to 2019Enrolled3,500ConditionsStroke, Ischemic, Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Morbidity
3 · Its place in the literature

Who cites it

419 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,036 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Prediction of individualised 6-month mortality risk in opioid use disorder.The British journal of psychiatry : the journal of mental science · 2026
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

359 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Julia Hippisley-CoxTower Building, University Park, Nottingham NG2 7RD. julia.hippisley-cox@nottingham.ac.uk
Carol Coupland
Yana Vinogradova
John Robson
Margaret May
Peter Brindle
Queen Mary University of London · GBUniversity of Bristol · GBUniversity of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo derive a new cardiovascular disease risk score (QRISK) for the United Kingdom and to validate its performance against the established Framingham cardiovascular disease algorithm and a newly developed Scottish score (ASSIGN).

designProspective open cohort study using routinely collected data from general practice.

settingUK practices contributing to the QRESEARCH database.

participantsThe derivation cohort consisted of 1.28 million patients, aged 35-74 years, registered at 318 practices between 1 January 1995 and 1 April 2007 and who were free of diabetes and existing cardiovascular disease. The validation cohort consisted of 0.61 million patients from 160 practices.

main outcome measuresFirst recorded diagnosis of cardiovascular disease (incident diagnosis between 1 January 1995 and 1 April 2007): myocardial infarction, coronary heart disease, stroke, and transient ischaemic attacks. Risk factors were age, sex, smoking status, systolic blood pressure, ratio of total serum cholesterol to high density lipoprotein, body mass index, family history of coronary heart disease in first degree relative aged less than 60, area measure of deprivation, and existing treatment with antihypertensive agent.

resultsA cardiovascular disease risk algorithm (QRISK) was developed in the derivation cohort. In the validation cohort the observed 10 year risk of a cardiovascular event was 6.60% (95% confidence interval 6.48% to 6.72%) in women and 9.28% (9.14% to 9.43%) in men. Overall the Framingham algorithm over-predicted cardiovascular disease risk at 10 years by 35%, ASSIGN by 36%, and QRISK by 0.4%. Measures of discrimination tended to be higher for QRISK than for the Framingham algorithm and it was better calibrated to the UK population than either the Framingham or ASSIGN models. Using QRISK 8.5% of patients aged 35-74 are at high risk (20% risk or higher over 10 years) compared with 13% when using the Framingham algorithm and 14% when using ASSIGN. Using QRISK 34% of women and 73% of men aged 64-75 would be at high risk compared with 24% and 86% according to the Framingham algorithm. UK estimates for 2005 based on QRISK give 3.2 million patients aged 35-74 at high risk, with the Framingham algorithm predicting 4.7 million and ASSIGN 5.1 million. Overall, 53 668 patients in the validation dataset (9% of the total) would be reclassified from high to low risk or vice versa using QRISK compared with the Framingham algorithm.

conclusionQRISK performed at least as well as the Framingham model for discrimination and was better calibrated to the UK population than either the Framingham model or ASSIGN. QRISK is likely to provide more appropriate risk estimates to help identify high risk patients on the basis of age, sex, and social deprivation. It is therefore likely to be a more equitable tool to inform management decisions and help ensure treatments are directed towards those most likely to benefit. It includes additional variables which improve risk estimates for patients with a positive family history or those on antihypertensive treatment. However, since the validation was performed in a similar population to the population from which the algorithm was derived, it potentially has a "home advantage." Further validation in other populations is therefore required.

Indexed as

AdultAgedAlgorithmsCardiovascular DiseasesCohort StudiesFemaleHumansMaleMiddle AgedProspective StudiesRisk AssessmentRisk FactorsUnited Kingdom

Identifiers

PMID17615182
PMCPMC1925200
OpenAlexW2049977108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.